You just read:

Janssen Submits New Drug Application to U.S. FDA Seeking Approval of Erdafitinib for the Treatment of Metastatic Urothelial Cancer

News provided by

Janssen Pharmaceutical Companies of Johnson & Johnson

Sep 18, 2018, 16:30 ET